Comparative Analysis of MAR and Terminator Elements in Controlling Stable EPO Expression in CHO-K1 Cells
Advanced Pharmaceutical Bulletin · 2026-06-29
DOI: 10.34172/apb.45955 ↗At a glance
Journal article in Advanced Pharmaceutical Bulletin, published online on 2026-06-29. Written by Fatemeh Jalali and 5 co-authors. Institution: Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran. The full text is freely available in PubMed Central.
Abstract (original language)
Purpose
Modulating chromatin organization and post-transcriptional regulation are critical for improving recombinant protein production . The human β-globin MAR (β-MAR) enhances transgene expression through nuclear matrix tethering, whereas the β-globin terminator (β-TERM) is implicated in transcriptional termination . However, their combined effects, particularly in stable erythropoietin (EPO) expression in CHO-K1 cells, remain less understood.
Methods
A codon-optimized EPO sequence were cloned into four expression plasmids. Stable polyclonal CHO-K1 cell pools were generated and assessed for transgene copy number, steady-state mRNA abundance, and EPO secretion . In parallel, in silico RNA-binding protein (RBP) profiling was performed for the polyA signal and β-TERM, followed by protein–protein interaction network analysis, hub-gene identification, and functional enrichment to elucidate post-transcriptional regulatory mechanisms.
Results
Incorporation of β-MAR resulted in remarkable EPO expression, yielding approximately 15 gene copies per cell, a 5.3-fold increase in mRNA abundance, and an EPO titer of 28.3 mIU/mL (3.4-fold over control). In contrast, the β-TERM element alone exerted minimal effects on protein output, while the combined β-MAR+β-TERM construct showed intermediate performance, suggesting partial attenuation of β-MAR activity. Network analysis of RBPs associated with poly(A) and β-TERM sequences revealed a highly interconnected post-transcriptional regulatory network enriched in RNA processing and stability factors. Notably, HNRNPK, HNRNPA2B1, U2AF2, FUS, and CELF1 were identified as central hub genes, indicating that β-TERM predominantly influences RNA fate rather than directly enhancing translation.
Conclusion
These findings establish β-MAR as a dominant chromatin-level enhancer of stable EPO expression in CHO cells and demonstrate that β-TERM engages RBP-centered post-transcriptional networks in a context-dependent and non-additive manner. This integrative analysis provides mechanistic insight for the rational design of expression cassettes in mammalian cell engineering and biopharmaceutical production.
Subjects
Author keywords
Authors and institutions
- Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
- Department of Medical Biotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran.
- Department of Plant Breeding and Biotechnology, College of Plant Production, Gorgan University of Agricultural Sciences and Natural Resources, Gorgan, Iran.
- Arya Tina Gene (ATG) Biopharmaceutical Company, Gorgan, Iran.
ORCID profiles: Fatemeh Jalali, Majid Shahbazi
Cite
APA
Jalali, F., Abdoli, S., Shamsabadi, F., Yamchi, A., Kianmehr, A., & Shahbazi, M. (2026). Comparative Analysis of MAR and Terminator Elements in Controlling Stable EPO Expression in CHO-K1 Cells. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.45955
Vancouver
Jalali F, Abdoli S, Shamsabadi F, Yamchi A, Kianmehr A, Shahbazi M. Comparative Analysis of MAR and Terminator Elements in Controlling Stable EPO Expression in CHO-K1 Cells. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.45955
BibTeX
@article{Jalali2026,
author = {Jalali, Fatemeh and Abdoli, Shahriyar and Shamsabadi, Fatemeh and Yamchi, Ahad and Kianmehr, Anvarsadat and Shahbazi, Majid},
title = {Comparative Analysis of MAR and Terminator Elements in Controlling Stable EPO Expression in CHO-K1 Cells},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
doi = {10.34172/apb.45955}
}
EUVIMED